Xarelto on Prevention of Stroke and Non-Central Nervous Systemic (CNS) Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation (NVAF)
Phase of Trial: Phase IV
Latest Information Update: 29 Jan 2019
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Embolism; Stroke
- Focus Adverse reactions
- Acronyms XARENAL
- Sponsors Bayer
- 18 Jan 2019 Planned primary completion date changed from 2 Dec 2019 to 1 Dec 2020.
- 20 Dec 2018 Status changed from not yet recruiting to recruiting.
- 26 Nov 2018 New trial record